Saturday 17 October 2026
Export ABPO’s income statement to Excel — free account
Abpro Holdings Inc.
ABPO Healthcare Biotechnology
Abpro Holdings Inc.’s revenue for fiscal 2024 (year ended December 2024) was $183,000.00, up 50.0% from fiscal 2023. In the quarter to June 2026, EPS grew 89.3% and free cash flow was flat, each against the same quarter a year earlier.
0.36
0.05
−12.20%
Follow ABPO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (20.18%) | 0.33% | 24.90% | 130.01% |
+8 more TTM periods Free account |
|
| 46.10% | (0.68%) | (101.05%) | (454.26%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(63.92%) | 1.37% | 34.23% | 135.11% | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.12) | (1.47) | (2.70) | (3.53) | |
Free Cash Flow |
(6.59) | (6.58) | (6.03) | (9.22) | |
Capital Expenditures |
— | — | (0.02) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(526.20%) | (208.26%) | 73.51% | 60.47% | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(20.31) | (15.52) | (7.49) | (7.88) | |
Operating CF/Net income |
(3.28) | 199.48 | 2.08 | 0.42 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | (0.04) | (0.03) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.12) | (1.47) | (2.69) | (3.52) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates